| 1 |
34820552 | Resetting amino acid metabolism of cancer cells by ATB0,+-targeted nanoparticles for enhanced anticancer therapy. | 2022 Mar |
1 |
| 2 |
34157442 | Inhibition of GPX4 or mTOR overcomes resistance to Lapatinib via promoting ferroptosis in NSCLC cells. | 2021 Aug 27 |
3 |
| 3 |
34159337 | Discovery of pan-ErbB inhibitors protecting from SARS-CoV-2 replication, inflammation, and lung injury by a drug repurposing screen. | 2021 Jun 15 |
1 |
| 4 |
29453318 | Integration of Distinct ShcA Signaling Complexes Promotes Breast Tumor Growth and Tyrosine Kinase Inhibitor Resistance. | 2018 May |
1 |
| 5 |
28243326 | The research on lapatinib in autophagy, cell cycle arrest and epithelial to mesenchymal transition via Wnt/ErK/PI3K-AKT signaling pathway in human cutaneous squamous cell carcinoma. | 2017 |
1 |
| 6 |
26623720 | Immunohistochemical prediction of lapatinib efficacy in advanced HER2-positive breast cancer patients. | 2016 Jan 5 |
1 |
| 7 |
27402251 | ERRĪ± mediates metabolic adaptations driving lapatinib resistance in breast cancer. | 2016 Jul 12 |
2 |
| 8 |
27785067 | Everolimus enhances cellular cytotoxicity of lapatinib via the eukaryotic elongation factor-2 kinase pathway in nasopharyngeal carcinoma cells. | 2016 |
6 |
| 9 |
25692408 | PI3K-independent mTOR activation promotes lapatinib resistance and IAP expression that can be effectively reversed by mTOR and Hsp90 inhibition. | 2015 |
4 |
| 10 |
26134366 | Sensitization of HER2 Positive Breast Cancer Cells to Lapatinib Using Plants-Derived Isothiocyanates. | 2015 |
1 |
| 11 |
26516700 | Chemical probing of HER2-amplified cancer cells identifies TORC2 as a particularly effective secondary target for combination with lapatinib. | 2015 Dec 1 |
1 |
| 12 |
24675532 | Biomarker-guided sequential targeted therapies to overcome therapy resistance in rapidly evolving highly aggressive mammary tumors. | 2014 May |
2 |
| 13 |
23794518 | Autophagy stimulates apoptosis in HER2-overexpressing breast cancers treated by lapatinib. | 2013 Dec |
1 |
| 14 |
24124748 | [Effects of mammalian-target-of-rapamycin pathway on lapatinib resistance in breast cancer MDA-MB-231 cells]. | 2013 Jun 25 |
3 |
| 15 |
22043997 | Pharmacologic inhibition of mTOR improves lapatinib sensitivity in HER2-overexpressing breast cancer cells with primary trastuzumab resistance. | 2012 Feb |
5 |
| 16 |
22219388 | Obatoclax and lapatinib interact to induce toxic autophagy through NOXA. | 2012 Apr |
1 |
| 17 |
22407832 | Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy. | 2012 May 1 |
2 |
| 18 |
23089982 | PI3K independent activation of mTORC1 as a target in lapatinib-resistant ERBB2+ breast cancer cells. | 2012 Dec |
3 |
| 19 |
19574203 | mTOR inhibitors and the anti-diabetic biguanide metformin: new insights into the molecular management of breast cancer resistance to the HER2 tyrosine kinase inhibitor lapatinib (Tykerb). | 2009 Jul |
4 |
| 20 |
18283037 | Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb) in human breast carcinoma cells. | 2008 Jun |
4 |
| 21 |
19010894 | Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. | 2008 Nov 15 |
2 |